BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact
BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.
Zacks · 1天前
How Biomarin Beat Expectations in Q2
You won't find many people who would complain about BioMarin Pharmaceutical's (NASDAQ: BMRN) performance so far this year. Here are the highlights from BioMarin's Q2 update. The company announced a net loss in the second quarter of $29.2 million, or $0.16 pe
Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. includin
Motley Fool · 1天前
BioMarin Pharmaceutical EPS misses by $0.04, beats on revenue, expects FY20 GAAP profit
BioMarin Pharmaceutical (NASDAQ:BMRN): Q2 GAAP EPS of -$0.16 misses by $0.04. Revenue of $429.5M (+10.8% Y/Y) beats by $12.1M. For the FY20, BioMarin conti
seekingalpha · 2天前
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Beat Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 100.00% and 2.74%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.
Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 44.83 percent increase over losses of $(0.29) per
Benzinga · 2天前
BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)